KRYS logo

KRYS
Krystal Biotech Inc

1,771
Mkt Cap
$7.65B
Volume
2.00
52W High
$298.30
52W Low
$122.80
PE Ratio
38.25
KRYS Fundamentals
Price
$261.80
Prev Close
$260.95
Open
$260.95
50D MA
$264.85
Beta
0.98
Avg. Volume
283,201.49
EPS (Annual)
$6.84
P/B
6.27
Rev/Employee
$1.32M
$6,565.67
Loading...
Loading...
News
all
press releases
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS
SG Americas Securities LLC raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 469.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,909 shares...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Wolfe Research Initiates Coverage on Krystal Biotech (NASDAQ:KRYS)
Wolfe Research started coverage on Krystal Biotech in a research note on Friday. They issued a "peer perform" rating on the stock...
MarketBeat·11d ago
News Placeholder
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from Brokerages
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. Two analysts...
MarketBeat·11d ago
News Placeholder
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Zacks·18d ago
News Placeholder
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
Zacks·18d ago
News Placeholder
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
Zacks·18d ago
News Placeholder
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·19d ago
News Placeholder
Decheng Capital LLC Sells 33,700 Shares of Krystal Biotech, Inc. $KRYS
Decheng Capital LLC lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 51.1% during the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·22d ago
News Placeholder
Avoro Capital Advisors LLC Purchases 117,777 Shares of Krystal Biotech, Inc. $KRYS
Avoro Capital Advisors LLC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 4.4% in the third quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·24d ago
News Placeholder
First Trust Advisors LP Has $43.85 Million Stake in Krystal Biotech, Inc. $KRYS
First Trust Advisors LP grew its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 11.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·26d ago
<
1
2
...
>

Latest KRYS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.